...
首页> 外文期刊>Journal of Molecular Endocrinology >ABCG2/BCRP gene expression is related to epithelial–mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)
【24h】

ABCG2/BCRP gene expression is related to epithelial–mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1)

机译:ABCG2 / BCRP基因表达与甲状腺乳头状癌细胞系(TPC-1)中的上皮-间质转化诱导基因相关

获取原文
           

摘要

Tumor malignancy is associated with the epithelial–mesenchymal transition (EMT) process and resistance to chemotherapy. However, little is known about the relationship between the EMT and the multidrug-resistance gene in thyroid tumor progression. We investigated whether the expression of the ABCG2/BCRP gene is associated with ZEB1 and other EMT inducer genes involved in tumor dedifferentiation. We established a subpopulation of cells that express the ABCG2/BCRP gene derived from the thyroid papillary carcinoma cell line (TPC-1), the so-called TPC-1 MITO-resistant subline. The most relevant findings in these TPC-1 selected cells were a statistically significant upregulation of ZEB1 and TWIST1 (35- and 15-fold change respectively), no changes in the relative expression of vimentin and SNAIL1, and no expression of E-cadherin. The TPC-1 MITO-resistant subline displayed a faster migration and greater invasive ability than parental cells in correlation with a significant upregulation of the survivin (BIRC5) gene (twofold change, P0.05). The knockdown of ZEB1 promoted nuclear re-expression of E-cadherin, reduced expression of vimentin, N-cadherin, and BIRC5 genes, and reduced cell migration (P0.05). Analysis of human thyroid carcinoma showed a slight overexpression of the ABCG2/BCRP at stages I and II (P0.01), and a higher overexpression at stages III and IV (P0.01). SNAIL1, TWIST1, and ZEB1 genes showed higher expression at stages III and IV than at stages I and II. E- and N-cadherin genes were upregulated at stages I and II of the disease (ninefold and tenfold change, respectively, P0.01) but downregulated at stages III and IV (fourfold lower, P0.01). These results could be a promising starting point for further study of the role of the ABCG2/BCRP gene in the progression of thyroid tumor.
机译:肿瘤恶性与上皮-间质转化(EMT)过程和对化疗的耐药性有关。然而,关于甲状腺肿瘤进展中的EMT和多药耐药基因之间的关系知之甚少。我们调查了ABCG2 / BCRP基因的表达是否与ZEB1和其他EMT诱导基因涉及肿瘤的去分化。我们建立了一个细胞亚群,它们表达源自甲状腺乳头状癌细胞系(TPC-1)的ABCG2 / BCRP基因,即所谓的TPC-1 MITO抗性亚系。在这些TPC-1选择的细胞中,最相关的发现是ZEB1和TWIST1在统计学上显着上调(分别变化了35和15倍),波形蛋白和SNAIL1的相对表达没有变化,而E-钙粘蛋白的表达没有变化。与Survivin(BIRC5)基因的显着上调有关,TPC-1 MITO抗性亚系显示出比亲代细胞更快的迁移和更大的侵袭能力(两倍变化,P <0.05)。敲低ZEB1促进E-钙粘蛋白的核表达,减少波形蛋白,N-钙粘蛋白和BIRC5基因的表达,并减少细胞迁移(P <0.05)。对人甲状腺癌的分析显示,在第一和第二阶段ABCG2 / BCRP略有过表达(P <0.01),在第三和第四阶段ABCG2 / BCRP的过表达较高(P <0.01)。 SNAIL1,TWIST1和ZEB1基因在III和IV期的表达高于I和II期。 E-和N-钙粘着蛋白基因在疾病的第一和第二阶段被上调(分别变化了九倍和十倍,P <0.01),但是在第三和第四阶段被下调(降低了四倍,P <0.01)。这些结果可能是进一步研究ABCG2 / BCRP基因在甲状腺肿瘤进展中的作用的有希望的起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号